Xtandi is a cancer medicine used to treat men with prostate cancer.
It is used when the cancer is metastatic (has spread to other parts of the body), castration resistant (worsens despite treatment to lower production of testosterone or after surgical removal of the testes) and when either:
- treatment with docetaxel (a cancer medicine) has not worked or no longer works; or
- hormone therapy has not worked, and the patient has either no symptoms or mild symptoms and does not yet require chemotherapy (another type of cancer treatment).
Xtandi can also be used for castration-resistant prostate cancer that is not metastatic (has not yet spread) but is at high risk of doing so.
The medicine contains the active substance enzalutamide.
Xtandi : EPAR - Medicine overview (PDF/84.65 KB)
First published: 02/07/2013
Last updated: 25/01/2019
Xtandi : EPAR - Risk-management-plan summary (PDF/528.91 KB)
First published: 25/01/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Astellas Pharma Europe B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
23/10/2018 Xtandi - EMEA/H/C/002639 - II/0039/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Xtandi is indicated for:
• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
• the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).
• the treatment of adult men with metastatic castration resistant prostate cancer whose disease has progressed on or after docetaxel therapy.